Trial · NCT05431283
Real-world Effectiveness of Tofacitinib on Ulcerative Colitis Associated Spondyloarthropathy
NCT05431283, Unknown, Italian Group for the study of Inflammatory Bowel Disease (IG-IBD)
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Real-world Effectiveness of Tofacitinib on Ulcerative Colitis Associated Spondyloarthropathy. Trials, record NCT05431283. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT05431283
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Real-world Effectiveness of Tofacitinib on Ulcerative Colitis Associated Spondyloarthropathy
- NCT number
- NCT05431283
- Status
- Unknown
- Enrollment
- 100 participants, estimated
- Lead sponsor
- Italian Group for the study of Inflammatory Bowel Disease (IG-IBD)
- Conditions
- Ulcerative Colitis, Spondyloarthropathy
- Interventions
- Tofacitinib
- First posted
- 2022-06-24
- Last updated
- 2022-06-24
Source ClinicalTrials.gov
Registered outcomes14
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | joint response and steroid free joint response | week 8 | evaluate the rate of patients achieving joint response and steroid free joint response on Ulcerative Colitis-associated spondyloarthropathy at week 8, 24, and 52 |
| Primary | joint response and steroid free joint response | week 24 | evaluate the rate of patients achieving joint response on Ulcerative Colitis-associated spondyloarthropathy |
| Primary | joint response and steroid free joint response | week 52 | evaluate the rate of patients achieving joint response and steroid free joint response on Ulcerative Colitis-associated spondyloarthropathy |
| Secondary | clinical intestinal response CIR | week 8 | To assess the rate of patients achieving a clinical intestinal response CIR for Ulcerative Colitis |
| Secondary | clinical intestinal response CIR | week 24 | To assess the rate of patients achieving a clinical intestinal response CIR for Ulcerative Colitis |
| Secondary | clinical intestinal response CIR | week 52 | To assess the rate of patients achieving a clinical intestinal response CIR for Ulcerative Colitis |
| Secondary | steroid free clinical intestinal remission | week 52 | To assess the rate of patients achieving a steroid free clinical intestinal remission for Ulcerative Colitis |
| Secondary | impact of Ulcerative Colitis | week 8 | To assess the impact of Ulcerative Colitis and therapy with TOFA on Work Productivity and Activity Impairment through the administration of WPAI Questionnaire at baseline |
| Secondary | impact of Ulcerative Colitis | week 24 | To assess the impact of Ulcerative Colitis and therapy with TOFA on Work Productivity and Activity Impairment through the administration of WPAI Questionnaire at baseline |
| Secondary | impact of Ulcerative Colitis | week 52 | To assess the impact of Ulcerative Colitis and therapy with TOFA on Work Productivity and Activity Impairment through the administration of WPAI Questionnaire at baseline |
1 to 10 of 14Source ClinicalTrials.gov
See all 14 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT05431283
GET https://conductscience.org/api/trials/v1/NCT05431283/registered